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Abstract 45 
Lipoxin A4 (LXA4) as endogenously produced lipid mediators promotes the resolution of inflammation. 46 
Previously, we have demonstrated that LXA4 stimulated alveolar fluid clearance (AFC) through alveolar 47 
epithelial sodium channel gamma (ENaC-?). In this study, we sought to investigate the mechanisms of 48 
LXA4 in modulating ENaC-? on LPS-induced inflammatory lung injury. MiR-21 was up-regulated in LPS 49 
challenging and down-regulated by LXA4 administration in vivo and in vitro. Serum miR-21 concentration 50 
was also elevated in acute respiratory distress syndrome (ARDS) patients as compared with healthy 51 
volunteers. LPS increased miR-21 expression by activation of activator protein 1 (AP-1). In A549 cells, 52 
miR-21 up-regulated phosphorylation of AKT activation via inhibition of PTEN therefore reduced the 53 
expression of ENaC-?. In contrast, LXA4 reversed LPS-depressed ENaC-? expression through inhibiting 54 
AP-1 and activating PTEN. In addition, miR-21 inhibitor mimicked the effects of LXA4; over-expression of 55 
miR-21 abolished the protective effects of LXA4. Finally, both AKT and ERK inhibitor (LY294002 and 56 
UO126) blocked LPS’s effects on the depression of ENaC-?. However, LXA4 only inhibited LPS-induced 57 
phosphorylation of AKT. In summary, LXA4 activates ENaC-? in part via miR-21/PTEN/AKT signaling 58 
pathway. 59 
 60 
Abbreviations 61 
AFC: alveolar fluid clearance 62 
AP-1: activator protein 1 63 
ARDS: acute respiratory distress syndrome 64 
CDS: coding sequence 65 
ENaC: epithelial sodium channel 66 
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LPS: lipopolysaccharide 67 
LXA4: lipoxin A4 68 
PTEN: phosphatase and tensin homolog 69 
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Acute respiratory distress syndrome (ARDS) is a devastating syndrome characterized by dysregulated 89 
inflammation and alveolar barrier disruption that impairs pulmonary gas exchange, leading to refractory 90 
arterial hypoxemia and respiratory failure 1, 2. Bacterial or viral pneumonia and sepsis are the most 91 
common causes of acute lung injury (ALI) and ARDS 1, wherein Gram-negative bacteria are a prominent 92 
cause. Lipopolysaccharide (LPS), the outer membrane of Gram-negative bacteria, is one of the mainly 93 
pro-inflammatory reaction factors in ALI, leading to neutrophil recruitment and pulmonary edema3. After 94 
decades of efforts, ARDS has a declined mortality, perhaps secondary to more widespread use of 95 
lung-protective ventilation, reductions in nosocomial infections and supportive care2, 4.  96 
Recently, the critical importance of timely and effective removal of excessive alveolar edema, namely 97 
alveolar fluid clearance (AFC), has being better recognized in ARDS5, 6. It is now well established that the 98 
mechanisms of AFC is the alveolar fluid cleared by active Na+ transport 7, which across the alveolar 99 
epithelium via apical alveolar epithelial sodium channel (ENaC) 8-10 and through basolateral 100 
Na+-K+-ATPases 9, 11, then the water passively moves from the air spaces to the alveolar intersititium as 101 
the result of transepithelial osmotic gradient caused by active Na+ transport. Hence, both ENaC and 102 
Na+-K+-ATPases are pivotal in timely and effective removal of excessive alveolar edema fluid 12. 103 
There is a growing appreciation that there have short-term regulatory and long-term regulatory 104 
mechanisms in active Na+ transport. Short-term regulatory mechanisms mainly possessed by dopamine 105 
and ?-adrenergic agonists; transcriptional and posttranscriptional mechanisms response to long-term 106 
regulation 11. We previously reported that intravenous ?-agonists (salbutamol) reduced extravascular 107 
lung water in ARDS patients13-16. However, we found salbutamol significantly increased 28-day mortality 108 
because of its side effects such as tachycardia, arrhythmias, and lactic acidosis in a multicenter, 109 
randomized, controlled clinical trial17. Therefore, we need to identify some new therapeutic agents. 110 
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Lipoxins (LX) are eicosanoids formed during inflammation via transcellular biosynthetic routes that 111 
posses distinct anti-inflammatory and proresolution properties, including the repression of 112 
proinflammatory cytokine production, inhibition of leukocyte-mediated injury, and stimulation of 113 
macrophage clearance of apoptotic neutrophils 18, 19. LXA4 have emerged as founding members of the 114 
first class of lipid mediators that can function as “braking signals” in inflammation, and are “switched on” 115 
in the resolution phase of an inflammatory response. We previously described distinct pro-resolution and 116 
anti-edema properties of LXA4 and aspirin-triggered LXA4 in rat ALI model10, 20, 21. We found LXA4 117 
significantly stimulated AFC through up-regulated ENaC-? protein expression10, which presents as 118 
regulative subunit of ENaC 22. Thus, LXA4 is a useful tool and offer leads for developing novel therapeutic 119 
intervention. 120 
MicroRNAs (miRNAs) are a class of gene products that recently were implicated in several lung 121 
diseases23-25. Importantly, miRNAs emerge as novel biomarkers 26 and therapeutic strategies27. Recently 122 
studies revealed that miR-21 was dynamically regulated in LPS-induced ALI28, 29. Also, researches have 123 
showed that miR-16 up-regulated ENaC-? 30, miR-101 and miR-144 targeted cystic brosis 124 
transmembrane conductance regulator (CFTR) 3’ UTR 31, miR-96 and miR-330 bound to the 3' UTR of 125 
aquaporin 5 (AQP5) 32. Previous studies demonstrated that each specialized pro-resolving mediators 126 
(SPM) regulated a distinct panel of miRNAs33-35. More recently, LXA4 exhibited antifibrotic properties by 127 
up-regulation let-7c expression in renal fibrosis36. However, whether LXA4 augment AFC through a 128 
particular miRNA in LPS-induced ALI, if so, what the underlying mechanisms are, remain unclear. 129 
In the present study, we investigated the central role on miR-21 in LPS-dependent inflammatory lung 130 
injury. Based on in silico bioinformatic analysis and real-time PCR, we focused on miR-21 and its potential 131 
target ENaC-? mRNA. We also evaluated ARDS patients serum miR-21 level. Additionally, we investigated 132 
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the effect of LXA4 on the protein expression of ENaC-? and PTEN, and the phosphorylation of AKT and ERK133 
in vitro. Finally, to better understand the mechanisms of action of LXA4, we used miR-21 mimic, miR-21 134 
inhibitor, AP-1 inhibitor (SR11302), AKT inhibitor (LY294002), and ERK inhibitor (UO126) to investigate 135 
how this signaling pathway regulates ENaC-? protein expression. 136 
 137 
 138 
Materials and Methods 139 
Reagents 140 
LPS, LY294002 (AKT inhibitor) and U0126 (ERK inhibitor) were obtained from Sigma-Aldrich (St. Louis, 141 
MO). LXA4 was from Cayman Chemical Company (Ann Arbor, MI). SR11302 (AP-1 inhibitor) was 142 
purchased from Tocris Bioscience (Bristol, UK). RPMI 1640, fetal bovine serum (FCS), trypsin and 143 
enzyme-free cell dissociation buffer were purchased from Gibco (Grand Island, NY). Penicillin and 144 
streptomycin in saline citrate buffer were from Invitrogen (Carlsbad, CA).  145 
 146 
Animals 147 
Specific pathogen-free adult male SD rats, weighing 250-300g, obtained from Slac Laboratory Animal 148 
(Shanghai, China), were housed under controlled temperature and humidity in a day-night cycle, with 149 
free access to standard laboratory food and water. The study was approved by Animal Studies Ethics 150 
Committee of Wenzhou Medical University. 151 
 152 
Cell culture  153 
A549 Cells were cultured in RPMI 1640 containing 10% FCS with 100 U/ml penicillin, and 100 ?g/ml 154 
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streptomycin at 1 x 106/cm2, and incubated in a humidified atmosphere with 5% CO2 at 37°C. Before 155 
stimulation or transfection, cells were cultured overnight in 1% FBS. 156 
 157 
Study participants and sample processing 158 
All patients and healthy volunteers provided written informed consents and this study complied with the 159 
declaration of Helsinki and was approved by the Committee on Ethics of the Second Affiliated Hospital of 160 
Wenzhou Medical University. Study enrollment occurred between January to June 2014. ARDS was 161 
defined and classified according to the Berlin definition 37. Following the Berlin definition, diagnostic 162 
criteria for ARDS rely on 4 categories: 1) timing: within 1 week of a known clinical insult or new or 163 
worsening respiratory symptoms; 2) radiography: bilateral opacities - not fully explained by effusions, 164 
lobar/lung collapse or nodule; 3) origin of lung edema: respiratory failure not fully explained by cardiac 165 
failure or fluid overload, and 4) oxygenation impairment: subdivided into 3 categories according to the 166 
degree of hypoxemia severity (mild, moderate and severe). Eligible patients were at least 18 years of age 167 
and diagnosed within 48 hours with a PaO2/FiO2 ratio of < 300. Exclusion criteria included pre-existing 168 
severe disease of any major organs, pregnancy, pulmonary hypertension, malignant disease, human 169 
immunodeficiency virus (HIV) infection or if informed consent could not be obtained. Volunteers were not 170 
taking any medications for 2 weeks before commencement of the study. 171 
Blood from ARDS patients and healthy volunteers were put into EDTA-containing tubes (BD Biosciences, 172 
New Jersey, USA). Tubes were rotated end-over-end at room temperature for 30 min and centrifuged 173 
(795 × g, 20 min, 4 °C) by Beckman JB-6 (Beckman Coulter, Danvers, MA). The serum samples were 174 
aliquoted into 1.5-mL RNase-free Eppendorf tubes (Ambion, Carlsbad, CA). 175 
 176 
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Bioinformatics analysis and miRNA prediction 177 
The microRNA databases and target prediction tool TargetScan 6.2 (Cambridge, MA) 178 
(http://www.targetscan.org/index.html) 38 and miRWalk (Mannheim, Germany) 179 
(http://mirwalk.uni-hd.de/) 39 were used to identify potential microRNA targets. 180 
 181 
Transfections and reporter assays 182 
Cells were transfected with miR-21 mimic, inhibitor, or negative controls (RiboBio, Guangzhou, China) 183 
according to manufacturer’s protocol. 184 
Human SCNN1G (ENaC-? mRNA) coding sequence (CDS) (828-835 bp) containing the putative binding 185 
sites of miR-21 were amplified by PCR, inserted into the firefly luciferase reporter vector 186 
pmiR-RB-REPORTTM (RiboBio, Guangzhou, China) between the restrictive sites Xho I and Not I, and 187 
validated by sequencing. Their mutant constructs with a mutation of the miR-21 seed sequence were 188 
generated with the mutagenic oligonucleotide primers, according to the manual of GeneTailor 189 
Site-Directed Mutagenesis System (Invitrogen, Carlsbad, CA). Cells were plated at 1*105 cells/well on 190 
24-well plates, and transfected with pmiR-RB-SCNN1G CDS (30 ng) or their mutant constructs. 191 
Twenty-four hrs post-transfection, firefly and Renilla luciferase activities were consecutively measured, 192 
according to the dual-luciferase assay manual (Promega, Madison, WI). The Renilla luciferase signal was 193 
normalized to the firefly luciferase signal for each individual analysis. 194 
 195 
Reverse transcription and real-time PCR 196 
Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA), according to the 197 
manufacturer’s instructions. Pri-miR-21, ENaC-? and PTEN mRNA were quantified by real-time PCR assay 198 
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using the SYBR Green real-time PCR Master Mix regents (Toyobo, Osaka, Japan) with GAPDH as the 199 
normalisation control. For determination of miRNAs expression, total RNA (2 ?g) was reversely 200 
transcribed with Bulge-Loop miRNA-specific reverse transcription-primers (RiboBio, Guangzhou, China). 201 
Real-time PCR reactions were done with SYBR Green real-time PCR Master Mix regents (Toyobo, Osaka, 202 
Japan) and Bulge-Loop primers (RiboBio, Guangzhou, China) on the CFX96 Real-Time PCR Detection 203 
System (Bio-Rad, Hercules, CA) with small nuclear RNA U6 as the normalisation control. For 204 
determination of serum miRNA concentration, specific TaqMan assays for miRs and the TaqMan 205 
Micro-RNA Reverse Transcription Kit were used, followed by real-time PCR using the Universal PCR 206 
Master Mix (Ambion, Carlsbad, CA) according to the manufacturer’s protocol with cel-miR-39 as the 207 
normalisation control. 208 
 209 
Western blot 210 
Western blotting analysis from A549 cells lysis solution was performed as described previously10. The 211 
protein extracts were separated in SDS-polyacrylamide gels and transferred to PVDF membranes. The 212 
primary antibodies used included the following: ?-actin (1:2000; Santa, Santa Cruz, CA), GAPDH 213 
(1:5000;  Bioworld,  St. Louis, MN), ENaC-? (1:1,000; Abcam, Cambridge, MA), PTEN (1:500; Abcam, 214 
Cambridge, MA), phospho-AKT (1:1000; Cell Signaling Technology, Boston, USA), AKT (1:1000; Cell 215 
Signaling Technology, Boston, USA), phospho-ERK (1:1000; Cell Signaling Technology, Boston, USA), 216 
ERK (1:1000; Cell Signaling Technology, Boston, USA). And after primary antibodies incubated overnight 217 
at 4°C, the secondary horseradish peroxidase-conjugated IgG which were either goat anti-mouse or goat 218 
anti-rabbit, were used at 1:3,000 dilution and imaged with the Image Quant LAS 4000 mini (GE 219 
Healthcare Bio-Sciences AB, Uppsala, Sweden). 220 
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 221 
Statistical analysis 222 
Data are presented as means ± SEM. All data were analyzed by the Student’s t test or by one-way ANOVA 223 
followed by Tukey’s post hoc test for multiple comparisons. Statistical analysis and graphs were done 224 
with GraphPad Prism 5.0 (GraphPad, San Diego, CA). Results with P ? 0.05 were considered statistically 225 
significant. 226 
 227 
 228 
Results 229 
Specific miRNAs are up-regulated in LPS challenging and down-regulated with LXA4 230 
administration 231 
In silico bioinformatic analysis (TargetScan and miRWalk) revealed that miR-181a/b, miR-340, miR-137 232 
were likely targeting the Na,K-ATPase ?1 3’-UTR, miR-29a/b/c were likely targeting the Na,K-ATPase ?1 233 
5’-UTR, and miR-21 was able to potentially regulate the expression of ENaC-? mRNA by binding to its 234 
CDS (Figure 1A). To investigate whether these miRNAs had roles in Na,K-ATPase ?1, Na,K-ATPase ?1 and 235 
ENaC-? mRNA post-transcriptional regulations, we next sought to determine whether LPS regulates 236 
these miRNAs expression and the effects of LXA4. Hierarchical clustering grouped these miRNAs into 237 
distinct clusters based on their relative abundance at the different treatment, in vivo and in vitro (Figure 238 
1B and C). In particular, among the few miRNAs highly expressed in the present of LPS, miR-21, miR-29b 239 
and miR-340 displayed >2.5-fold increases compared with control group and attenuated in the LXA4 240 
treatment. Conversely, a large group of miRNAs showed less vigorous increase (<0.4-fold changes). 241 
Among these, we focused on miR-21 because it showed consistent up-regulation at LPS stimulation and 242 
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down-regulation under LXA4 treatment in vivo and in vitro. Therefore, we next determined the 243 
expression levels of miR-21 along we previously described LPS-induced rat ALI model 40 using real-time 244 
PCR. MiR-21 remained up-regulated at LPS present and down-regulated at LXA4 treatment (Figure 2A). 245 
Consistent with results from in vivo, miR-21 was significantly up-regulated at the stimulation of LPS 246 
compared to the control group and attenuated in the LXA4 treatment in A549 cells (Figure 2B). 247 
MiR-21 serum concentration is elevated in ARDS 248 
As a demonstration of the potential importance of miR-21, we investigated miR-21 serum concentration 249 
in ARDS patients (see Supplemental Table S1). While miR-21 serum concentration was elevated in ARDS 250 
patients (at admission to the ICU and prior to therapeutic interventions) compared to healthy volunteers 251 
(n=4) (Figure 2C). 252 
 253 
AP-1 mediated LPS-induced miR-21 expression 254 
In order to clarify the regulatory mechanism by which LPS and/or LXA4 affect miR-21 expression, we 255 
analyzed primary transcripts of miR-21 gene (pri-miR-21) in A549 cells. LPS increased the amounts of 256 
pri-miR-21, whereas LXA4 abolished the LPS-induced pri-miR-21 expression (Figure 3A), which 257 
consistent with the mature miR-21, indicating that LPS and LXA4 regulate miR-21 biosynthesis at the 258 
transcriptional level. 259 
For AP-1 is one of the conserved enhancer elements in the miR-21 promoter region41, 42, we next explored 260 
whether AP-1 was involved in LPS and/or LXA4 mediated miR-21 biosynthesis. Indeed, pretreatment of 261 
the A549 cells with the selective AP-1 inhibitor retinoid SR11302 43 reduced the production of 262 
LPS-induced miR-21, in a dose- and temporal-dependent pattern. In all responses, the miR-21 263 
expression was decreased dose-dependently with a concentration of 10nM producing a maximal effect 264 
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(Figure 3B). The dynamic expression of miR-21 decreased initially at 4 h with recovery occurring at 24 h 265 
and 6-12 h producing a maximal effect (Figure 3C). In subsequent experiment, the miR-21 expression 266 
was decreased 35% in the treatment of 10nM SR11302 for 12h, meanwhile, LXA4 significantly decreased 267 
LPS-induced miR-21 expression (Figure 3D). 268 
 269 
LXA4 attenuates LPS-depressed ENaC-? expression through inhibition of miR-21, but miR-21 270 
does not target ENaC-? mRNA directly 271 
We previously demonstrated that LPS depressed ENaC-? protein expression, and LXA4 reversed the 272 
repression in primary rat alveolar type  epithelial cells10. Therefore, we hypothesized that LXA4 273 
attenuated expression of LPS-induced miR-21 might underlie the protective mechanism of LXA4. Firstly, 274 
we observed that LPS stimulated a significant reduction in ENaC-? mRNA and protein expression. 275 
However, under the treatment of LXA4 and SR11302, ENaC-? expression was increased (Figure 4A and B). 276 
We therefore proposed that miR-21 maybe a pivotal mediator of LPS-deduced ENaC-? expression. 277 
Secondly, to test this hypothesis, we transfected miR-21 mimic or inhibitor in A549 cells resulting in a 278 
1000-fold induction or 2.2-fold repression in miR-21 expression levels, respectively (See Supplemental 279 
Figure S1). However, there was no significant change in ENaC-? protein expression (Figure 4C and D). 280 
Thirdly, to further address weather miR-21 involved in LPS-depressed ENaC-? expression, A549 cells 281 
stimulated with LPS (1 ?g/ml) for 8 hours after transfection of miR-21 mimic aggravated LPS-depressed 282 
ENaC-? protein expression and miR-21 inhibitor attenuated the depression (Figure 4E and F). These data 283 
suggested that up-regulation of miR-21 by LPS was necessary for subsequent down-regulation of ENaC-? 284 
expression. Furthermore, miR-21 mimic abolished the protective effect of LXA4 in attenuating 285 
LPS-mediated ENaC-? depression (Figure 4G and H). Conversely, ENaC-? protein expression was induced 286 
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upon miR-21 inhibitor transfection after LPS stimulation (Figure 4I and J). Together, these findings 287 
indicated that LXA4 possessed protective effect upon ENaC-? protein expression through down-regulated 288 
miR-21 expression. Finally, luciferase reporter assays containing wildtype and mutant seed region 289 
miR-21 binding site of the ENaC-? mRNA CDS confirmed that there did not have the interaction between 290 
miR-21 mimic and this site (Figure 4K).  291 
LXA4 attenuated LPS deduced ENaC-? expression via miR-21/PTEN pathway 292 
Given the foregoing evidence for phosphatase and tensin homolog (PTEN) is down-regulated in 293 
LPS-induced rat ALI model44, and miR-21 is a direct target of PTEN45, we investigated miR-21 target gene 294 
PTEN expression in LPS challenging in vitro. A549 cells stimulated with LPS resulted in significant 295 
down-regulation of PTEN mRNA and protein. Conversely, LXA4 alleviated this effect, meanwhile, SR11302 296 
showed analogous result (Figure 5A, B and C). Moreover, transfection with miR-21 inhibitor significantly 297 
increased PTEN protein expression (Figure 5D and E). Furthermore, in A549 cells transfected with miR-21 298 
inhibitor, miR-21 silencing prevented LPS-mediated depression of PTEN and ENaC-? protein expression 299 
(Figure 5F, G, H and I). Together, these results indicated that miR-21/PTEN was the key signaling 300 
pathway underling the LXA4 attenuated LPS-depressed ENaC-? protein expression. 301 
 302 
LPS decreased ENaC-? protein expression in a miR-21/PTEN AKT and ERK dependent fashion 303 
AKT and ERK are regulated by miR-21/PTEN pathway46. Therefore, we addressed whether these signaling 304 
pathways were involved in the regulation of LPS on ENaC-? protein expression. Firstly, we tested the 305 
phosphorylation of AKT and ERK in LPS stimulated A549 cells. We observed phosphorylation of AKT and 306 
ERK with 30 minutes LPS stimulation in A549 cells, resulting significant increased phosphorylation of AKT 307 
and ERK (Figure 6A, B, C and D). A549 cells pretreated with AP-1inhibitor (SR11302), AKT inhibitor 308 
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(LY294002) and ERK inhibitor (U0126) abrogated LPS-decreased ENaC-? protein expression (Figure 6E 309 
and F). 310 
LXA4 augmented ENaC-? protein expression through attenuating LPS-induced 311 
phosphorylation of AKT 312 
In the addition of SR11302, LY294002 and LXA4 abolished LPS-induced up-regulation of phosphorylation 313 
of AKT (Figure 6A and B). However, only the addition of U0126 reversed LPS-induced up-regulation of 314 
phosphorylation of ERK, SR11302 and LXA4 failed (Figure 6C and D). Under pretreatment of LXA4, 315 
ENaC-? protein expression significantly elevated compared with LPS group (Figure 6E and F). Our data 316 
indicated that LXA4 attenuated LPS-depressed ENaC-? protein expression in part through 317 
miR-21/PTEN/AKT pathway. 318 
 319 
 320 
Discussion   321 
In the present study, we have identified a distinct role of LXA4 on miR-21 expression in LPS-induced 322 
inflammatory lung injury. Our data showed that miR-21 was up-regulated in LPS challenging and 323 
down-regulated with LXA4 administration in vivo and in vitro and serum miR-21 concentration was 324 
elevated in ARDS patients. MiR-21 up-regulated phosphorylation of AKT activation via inhibition of PTEN 325 
therefore reduced the expression of ENaC-?. However, LXA4 reversed LPS-depressed ENaC-? expression 326 
through inhibiting AP-1 and activating PTEN indicating that LXA4 activated ENaC-? via miR-21/PTEN/AKT 327 
signaling pathway (as summarized in Figure 7). 328 
We have reported the protective effects and anti-edema properties of LXA4 in oleic acid (OA) and 329 
LPS-induced rat ALI model10, 20, 21. To date, mechanisms associated with LXA4 in the resolution of AFC 330 
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remain of wide interest. Results presented herein are the novel evidences of miRNA expression profiling 331 
with treatment of LXA4 in LPS-induced inflammatory lung injury. Our results have confirmed that LPS 332 
induced a sustained expression of miR-21 in vivo and in vitro. However, LXA4 showed inhibition in miR-21 333 
expression. Sterghios et al.29, using mouse aerosilised LPS model, reported that miR-21 was 334 
up-regulated and showed time dependent increases, coincidence with our in vivo result. Lee et al. 335 
reported that miR-21 was also up-regulated throughout the 24 h following OA challenge, in time-course 336 
analysis of miRNAs expression in rat OA-induced ALI47. These in vitro and in vivo results suggest the 337 
importance of miR-21 in ALI. Coincidently, we also found augmentation in miR-21 serum concentration in 338 
ARDS patients. Therefore, miR-21 may become a novel biomarker to predict severity and outcome of 339 
ARDS in the future.340 
Pri-miR-21 also elevated in LPS stimulating and attenuated by LXA4 treatment, which implied 341 
transcriptional regulatory mechanism. AP-1, which binding site located in miR-21 promoter region, 342 
proved to be one of the conserved enhancer elements of miR-2141. Previous studies demonstrated that 343 
LXA4 and aspirin-triggered LXA4 reduced AP-1 activity in the present of LPS48. Here we used AP-1 inhibitor 344 
SR11302 abolished LPS-induced miR-21 expression in a dose- and temporal-dependent pattern. 345 
Moreover, LXA4 mimicked the effect of SR11302, through inhibition of the LPS-mediated AP-1 346 
pro-inflammation signal, which as a consequence may lead to depression of miR-21. 347 
ENaC-? presents as regulative subunit of ENaC promotes the resolution of AFC 9. Our results on miRNAs 348 
expression patterns and in silico predictions led us to propose that miR-21 mediated the effects of LXA4 349 
in promotion ENaC-? expression in inflammatory lung injury responses. This hypothesis was supported 350 
by our findings that under transfecting miR-21 mimic and inhibitor into A549 cells. Over-expression of 351 
miR-21 abolished the protective effects of LXA4 in LPS-deduced ENaC-? expression; however, miR-21 352 
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inhibitor mimicked the effects of LXA4. Our data clearly demonstrate that miR-21 had no effect on ENaC-? 353 
expression in physiological conditions. However, trasfection with miR-21 mimic or inhibitor exacerbated 354 
or derepressed LPS-depressed ENaC-? expression. Vaporidi K demonstrated that ectopic expression of 355 
miR-21 reduced lung compliance and increased alveolar-arterial oxygen difference and protein levels in 356 
bronchoalveolar lavage in ventilator-induced mouse ALI model49. Here, we observed that treated with 357 
miR-21 mimic abolished the protective effect of LXA4 on LPS-deduced ENaC-? expression. Additionally, 358 
both SR11302 and LXA4 reversed LPS-decreased ENaC-? protein expression. Our data demonstrates that 359 
down-regulation of miR-21 is a necessary step in LXA4 blunting LPS-deduced ENaC-? expression. 360 
Luciferase reporter assay demonstrated that miR-21 did not target ENaC-? mRNA directly. However, we 361 
observed the depression of PTEN expression under LPS stimulation, and prevented by LXA4 and SR11302 362 
pretreatment. Consistent with previous studies that up-regulated miR-21 depressed PTEN mRNA and 363 
protein expression in ventilator-induced and OA-stimulated rat ALI model47, 49. In addition, PTEN contains 364 
miR-21 binging site within 3’ UTR45. Hence, we provide evidence linking LPS-mediated up-regulation of 365 
miR-21 with down-regulation of PTEN mRNA and protein in alveolar epithelia. Furthermore, transfection 366 
of miR-21 inhibitor increased PTEN protein expression. Consequently, loss of miR-21, LPS-depressed 367 
PTEN and ENaC-? were attenuated, demonstrating the importance of this miR-21/PTEN pathway to LPS 368 
actions on PTEN and ENaC-? expression. This observation unveils a novel pathway wherein miR-21/PTEN 369 
responses for LXA4 in augmenting ENaC-? protein expression in LPS-stimulated inflammatory lung injury. 370 
Both AKT and ERK are downstream regulators of miR-21/PTEN pathway46. In addition to this, it is known 371 
that ENaC activity is regulated by a complex network of signaling pathways, including AKT and ERK 372 
pathways50. We previously demonstrated that AKT pathway has been shown to mediate LPS-induced 373 
decrease of CFTR protein expression in primary ATII cells20. LPS resulted in a rapid phosphorylation of 374 
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AKT and ERK, which reached the peak in 30 minutes20. In the current study, the addition of LY294002 375 
abrogated LPS-induced phosphorylation of AKT, meanwhile, the pretreatment of SR11302 and LXA4 376 
decreased phosphorylation of AKT to average 30 min after LPS stimulation in A549 cells. Interestingly, 377 
pretreatment of SR11302 and LXA4 failed to depress LPS-induced phosphorylation of ERK. It has been 378 
reported that Aspirin-triggered lipoxin A4 inhibited myeloperoxidase (MPO) suppression of neutrophil 379 
apoptosis via down-regulation of AKT and ERK51. In contrast, Prieto P suggested that pretreatment with 380 
LXA4 promoted a rapid activation of ERK after staurosporine challenge in RAW 264.7 cells52. These 381 
differences were probably a consequence of signaling convergence and cross talk between the AKT and 382 
ERK cascades.  383 
Although multiple studies exist regarding the regulation of ion channels by miRNAs30-32, our results 384 
demonstrate that miR-21/PTEN/AKT pathway involves in LXA4 and LPS regulation of ENaC-? protein 385 
expression. However, there are three aspects remain to be further addressed. Firstly, to verify the 386 
relationship between miR-21 and ARDS there needs to recruit more patients. Secondly, ENaC-? activity 387 
and trafficking such as ion and fluid transport need to be additionally evaluated53. Finally, the mechanism 388 
we demonstrated based on our in vitro study; it would be of interest to further substantiate our findings 389 
that miR-21/PTEN/AKT pathway contributes to the lung anti-edema effects of LXA4 in vivo. 390 
In this study, we have shown that down-regulation of miR-21 regulated ENaC-? expression via a 391 
PTEN/AKT signaling pathway after LXA4 treatment in LPS-dependent inflammatory lung injury. However, 392 
its potential actions on other pathological mechanisms may be contributing as a crucial mediator. MiR-21 393 
has been shown to affect ERK–MAP kinase signaling in cardiac fibroblasts, which in turn positively 394 
regulates cardiac fibroblast survival, leading to fibrosis, hypertrophy and cardiac dysfunction54. In a lately 395 
study demonstrated that miR-21 was activated and involved in the pathophysiologic processes of the 396 
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Ischemia/Reperfusion-induced acute kidney injury. Therefore, miR-21 can serve as potential targets for 397 
modulation by specific miR-21 antagomiRs27 to achieve protection effects55. Furthermore, miR-21 has 398 
been demonstrated to be a multi-faced miRNA42 and deregulated in almost all types of cancers and 399 
therefore was classified as an oncomiR56, especially in cardiovascular and pulmonary diseases. Hence, 400 
pharmacologically down-regulation of miR-21, namely miR-21 antagomiR or agents like LXA4, may be a 401 
new therapeutic entry point in the future. 402 
In conclusion, these data demonstrate that LXA4 alleviated LPS-depressed ENaC-? protein expression via 403 
miR-21/PTEN/AKT signaling pathway. Thus, treatment with LXA4 in down-regulation of miR-21 could 404 
represent novel targets in the treatment of the critically ill patients with inflammatory lung injury. Our 405 
findings reveal a novel mechanism of LXA4 in reversing LPS-deduced ENaC-? protein expression and LXA4 406 
may provide a new therapy for the resolution of inflammatory lung injury. 407 
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Titles and legends to figures  634 
Figure 1: LXA4-regulated miRNAs target genes with specific roles in alveolar fluid clearance. (A) The 635 
putative miRNAs binding sites locate in Na,K-ATPase ?1, ?1, or ENaC-? mRNA. (B) SD rats were injected 636 
with LXA4 (2 ?g/kg) or vehicle (1 ml Saline) 8 hours after LPS (20 mg/kg) stimulation through caudal vein, 637 
lung tissue homogenate samples are harvested 1 hour later (n=3 per group), and miRNA fractions were 638 
isolated. (C) A549 cells treated with LPS (1 ?g/ml) and/or LXA4 (100 nM) for 8 hours (n=4). Heat map 639 
cluster represents relative expression of 8 miRNAs determined with real-time PCR after normalization 640 
with U6. Relative expression intensities are indicated in a green-red color code based on ?Ct values. 641 
  642 
Figure 2: MiR-21 is increased in inflammatory lung injury. (A) SYBR Green real-time PCR validation of 643 
miR-21 expression levels in rats ALI model. SD rats were injected with LXA4 (2 ?g/kg) or vehicle (1 ml 644 
Saline) 8 hours after LPS (20 mg/kg) stimulation through caudal vein, lung tissue homogenate samples 645 
are harvested 1 hour later (n=3 per group). (B) miR-21 expression measured by SYBR Green real-time 646 
PCR in A549 cells treated with LPS (1 ug/ml) and/or LXA4 (100 nM) for 8 hours (n=4). (C) TaqMan 647 
real-time PCR detection of serum miR-21 level of ARDS patients at admission to ICU revealed (p=0.03, 648 
t-test) elevating of miR-21 in ARDS patients (n=4) as compared with healthy controls (n=4). Plots are 649 
displayed, where the long line indicates the median per group, and horizontal lines show 95% confidence 650 
interval. * P < 0.05 versus control group, # P < 0.05 versus LPS group, ** P < 0.01. 651 
 652 
Figure 3: LPS-simulated miR-21 expression depends on AP-1. (A) SYBR Green real-time PCR 653 
measurement of pri-miR-21 in A549 cells treated with LPS (1 ?g/ml) and/or LXA4 (100 nM) for 8 hours. 654 
Expression was normalized to GAPDH (n=4). (B) SYBR Green real-time PCR detection of dose-dependent 655 
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miR-21 expression in A549 cells stimulated with LPS and SR11302. A549 cells are pre-incubated with 656 
different concentrations of SR11302 for 30 min including 1, 10, 100, 1000, 10000 nM before LPS (1 657 
?g/ml 12 hours) treatment to measure miR-21 expression. (C) SYBR Green real-time PCR detection of 658 
temporal-dependent miR-21 expression in A549 cells stimulated with LPS and SR11302. A549 cells are 659 
pre-treated with SR11302 (1uM) for 30min then stimulated with LPS (1 ?g/ml) for 4, 6, 12, 24 hours to 660 
detect miR-21 expression (n=3). (D) miR-21 expression measured by SYBR Green real-time PCR in A549 661 
cells incubated with LPS (1 ?g/ml; 8 hours) after pre-treated with SR11302 (10 nM; AP-1 inhibitor) or 662 
LXA4 (100 nM) for 30 min (n=5). U6 expression is selected as endogenous control for normalization. 663 
Relative expression is calculated using the ??Ct method of analysis. * P < 0.05 versus control group, #664 
P < 0.05 versus LPS group. 665 
  666 
Figure 4: LXA4 attenuates LPS-depressed ENaC-? protein expression through miR-21, but miR-21 does 667 
not target ENaC-? mRNA. (A) SYBR Green real-time PCR and (B) Western blot measurement of ENaC-? 668 
mRNA and protein expression in A549 cells stimulated with LPS (1 ?g/ml) and/or LXA4 (100 nM) for 8 669 
hours (n=4). * P < 0.05 versus control group, # P < 0.05 versus LPS group. (C and D) Western blot and 670 
corresponding densitometry analysis of ENaC-? protein expression in A549 cells transfected with control 671 
mimic, miR-21 mimic, control inhibitor and miR-21 inhibitor (n=3). (E and F) Western blot and 672 
corresponding densitometry analysis of ENaC-? protein expression in A549 cells transfected with control 673 
mimic, miR-21 mimic, control inhibitor and miR-21 inhibitor with stimulation of LPS (1 ?g/ml; 8 hours) 674 
(n=4). * P < 0.05 versus control group, || P < 0.05 versus control mimic, § P < 0.05 versus control 675 
inhibitor. (G and H) Western blot and corresponding densitometry analysis of ENaC-? protein expression 676 
in A549 cells transfected with control mimic or miR-21 mimic and stimulated with LPS (1 ?g/ml) and/or 677 
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LXA4 (100 nM) for 8 hours (n=4). * P < 0.05. (I and J) Western blot and corresponding densitometry 678 
analysis of ENaC-? protein expression in A549 cells transfected with control inhibitor or miR-21 inhibitor 679 
and stimulated with LPS (1 ?g/ml) and/or LXA4 (100 nM) for 8 hours (n=3). * P < 0.05. (K) 680 
Luciferase/Renilla ratio results for 293T cells cotransfected with miR-21 or control miRNA mimic together 681 
with pmiR-RB-SCNN1G CDS (wild type or mutant) for 24 hours. 682 
 683 
Figure 5: MiR-21/PTEN pathway responses for LPS and LXA4 regulation of ENaC-?. (A) SYBR Green 684 
real-time PCR and (B) Western blot measurement of PTEN mRNA and protein expression in A549 cells 685 
incubated with LPS (1 ?g/ml; 8 hours) after pre-treated with SR11302 (10 nM; AP-1 inhibitor) or LXA4 686 
(100 nM) for 30 min (n=4). (C) Densitometry analysis of PTEN protein expression in B (n=3). * P < 0.05 687 
versus control group, # P < 0.05 versus LPS group. (D and E) Western blot and corresponding 688 
densitometry analysis of PTEN protein expression in A549 cells transfected with control mimic, miR-21 689 
mimic, control inhibitor and miR-21 inhibitor (n=3). Western blot and corresponding densitometry 690 
analysis of PTEN (F and G) and ENaC-? (H and I) protein expression in A549 cells transfected with control 691 
inhibitor or miR-21 inhibitor and stimulated with LPS (1 ?g/ml) and/or LXA4 (100 nM) for 8 hours (n=3). 692 
* P < 0.05. 693 
 694 
Figure 6: LXA4 augmented LPS decreased ENaC-? protein expression via miR-21/PTEN/AKT pathway. 695 
Western blot and corresponding densitometry analysis of p-AKT (A and B), p-ERK (C and D) and ENaC-? 696 
(E and F) protein expression in A549 cells stimulated with LPS (1 ?g/ml; 12 hours) after pre-incubated 697 
with SR11302 (10 nM; AP-1 inhibitor), LY294002 (10 ?M, PI3K/Akt inhibitor), U0126 (20 ?M, ERK 698 
inhibitor), or LXA4 (100 nM) for 30 min (n=3). * P < 0.05 versus control group, # P < 0.05 versus LPS 699 
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group. 700 
 701 
Figure 7: Schematic representation of miR-21/PTEN/AKT pathway in LXA4 regulation of LPS-depressed 702 
ENaC-? protein expression. Through inhibition of PTEN, miR-21 up-regulated phosphorylation of AKT 703 
activation therefore reduced the expression of ENaC-?. However, via inhibiting AP-1 and activating PTEN, 704 
LXA4 reversed LPS-depressed ENaC-? expression, unveiling a novel therapeutic entry point wherein LXA4 705 
activated ENaC-? through down-regulating miR-21 expression. 706 







Table S1 Patient Characteristics
Patient Sex Age,
yr 
C-reactive 
protein 
(mg/dL) 
WBC 
(× 109/ L) 
PaO2/FiO2
 ratio 
Clinical Disorder 
1 M 59 322 16.5 129 Pneumonia 
2 M 86 172 17.3 223 Aspiration of gastric contents 
3 F 82 180 27.5 179 Pneumonia and Sepsis 
4 M 65 172 13.7 152 Sepsis 
M, male; F, female; WBC, white blood cell count. 
